Isolation and characterization of malaria PfHRP2 specific V-NAR antibody fragments from immunized shark phage display library by Leow, C.H. et al.
Leow et al. Malar J          (2018) 17:383  
https://doi.org/10.1186/s12936-018-2531-y
RESEARCH
Isolation and characterization of malaria 
PfHRP2 specific  VNAR antibody fragments 
from immunized shark phage display library
Chiuan Herng Leow3* , Katja Fischer1, Chiuan Yee Leow3, Katleen Braet5, Qin Cheng4 and James McCarthy1,2
Abstract 
Background: Malaria rapid diagnostic tests (RDTs) represent an important antibody based immunoassay platform. 
Unfortunately, conventional monoclonal antibodies are subject to degradation shortening shelf lives of RDTs. The 
variable region of the receptor  (VNAR) from shark has a potential as alternative to monoclonal antibodies in RDTs due 
to high thermal stability.
Methods: In this study, new binders derived from shark  VNAR domains library were investigated. Following immuniza-
tion of a wobbegong shark (Orectolobus ornatus) with three recombinant malaria biomarker proteins (PfHRP2, PfpLDH 
and Pvaldolase), a single domain antibody (sdAb) library was constructed from splenocytes. Target-specific  VNAR 
phage were isolated by panning. One specific clone was selected for expression in Escherichia coli expression system, 
and study of binding reactivity undertaken.
Results: The primary  VNAR domain library possessed a titre of 1.16 × 106 pfu/mL. DNA sequence analysis showed 
82.5% of isolated fragments appearing to contain an in-frame sequence. After multiple rounds of biopanning, a highly 
dominant clone specific to PfHRP2 was identified and selected for protein production in an E. coli expression system. 
Biological characterization showed the recombinant protein expressed in periplasmic has better detection sensitiv-
ity than that of cytoplasmic proteins. Assays of binding activity indicated that its reactivity was inferior to the positive 
control mAb C1–13.
Conclusions: Target-specific bacteriophage  VNARs were successfully isolated after a series of immunization, demon-
strating that phage display technology is a useful tool for selection of antigen binders. Generation of new binding 
reagents such as  VNAR antibodies that specifically recognize the malaria biomarkers represents an appealing approach 
to improve the performance of RDTs.
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria remains one of the most life-threatening infec-
tious diseases in the world. Five species of Plasmodium 
cause malaria in humans. Of these species, infection with 
Plasmodium falciparum is the most prevalent and lethal, 
causing significant morbidity and mortality worldwide 
[1]. Most of the P. falciparum-detecting rapid diagnos-
tic tests (RDTs) target histidine-rich protein 2 (PfHRP2) 
[2]. PfHRP2 is a water-soluble protein that is produced 
by all asexual stages of P. falciparum including game-
tocytes. This protein is abundantly expressed in the red 
cell, released during rupture of infected red cells and can 
remain in the blood for up to 28 days after the initiation 
of anti-malarial therapy, making it an excellent biomarker 
for diagnosing P. falciparum infections [3]. Plasmodium 
lactate dehydrogenase (pLDH), and fructose 1,6-biphos-
phate aldolase (Aldolase) are biomarkers commonly used 
for the detection of non-P. falciparum human malaria 
infections (species specific or PAN specific) and P. vivax 
infections, respectively [4, 5].
Unfortunately, the degradation of sensitive capture 
and detecting antibody reagents in malaria RDTs [6] can 
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shorten the shelf lives of RDTs and may also result in false 
negative diagnosis and eventually delay the treatment 
time if undetected [7]. Antibodies with better stabil-
ity profiles would improve the stability of RDTs. How-
ever, despite early attempts to engineer antibodies into 
more robust antibody fragments [8, 9], separating the 
VH and VL domains while retaining antibody specificity 
has proven to be difficult [10, 11]. In nature, sharks are 
the most ancient phylogenetic vertebrate group possess-
ing the complete molecular components of an adaptive 
immune system [12, 13]. In contrast to immunoglobulin 
(Ig) isotypes in higher mammals, the immunoglobulin 
new receptor (IgNAR) of sharks are unusual antibodies 
that lack light chains and, therefore, exist as homodimers 
of a heavy chain [14]. Immune electron microscopy indi-
cated that the IgNAR heavy chain contains one variable 
domain of  (VNAR) and five constant (C) domains [15]. 
Similar to  VHH in the camelid family,  VNAR domains can 
function as soluble single domains which are capable 
of antigen binding [15]. These single domain fragments 
display excellent solubility and high thermostability due 
to substitutions of amino acids at VH–VL interaction, 
making the interface more hydrophilic compared to the 
hydrophobic interface present in conventional antibodies 
[14, 16].
Similar to the variable domains of conventional immu-
noglobulin scaffolds, shark  VNAR have been determined 
to have four highly conserved framework regions (FR) 
and three highly variable complementary determining 
regions (CDRs). The deletion of a large portion of FR2–
CDR2 has therefore made  VNAR the smallest variable 
domain, with size of ~ 12  kDa [14]. In addition, shark 
 VNAR domains possess an extraordinary CDR3 domain 
which is much longer than that of conventional anti-
bodies. Therefore, the penetration capability of  VNAR is 
perceived much easier to reach to the cleft region of the 
target antigen [17, 18]. Thus far,  VNAR is recognized as the 
smallest natural single domain antibodies (sdAbs) found 
to date in the animal kingdom [14, 19].
The selection of a suitable expression system is vital to 
ensuring the solubility and correct folding required for 
expression of functional  VNAR protein. Bacterial expres-
sion systems are often the first choice in the laboratories 
for the production of recombinant proteins for therapeu-
tic and diagnostic applications [20–22]. It is amenable to 
produce recombinant proteins for a range of biological 
applications [23].
Due to the high numbers of cysteine residues, the 
soluble expression of  VNAR constructs in bacterial hosts 
has been extensively studied by a range of laboratories 
[24, 25]. Thus far,  VNAR proteins have been reportedly 
expressed in bacteria system using proprietary expression 
vectors such as pIMS100 [25], pIMS147 [26], Pecan22 
[27, 28] pAK-300 [29], and pET-28a [30]. In addition, the 
PelB leader peptide has been commonly used as a fusion 
protein partner for bacterial periplasmic targeting [31, 
32].
In the present work, new antigen binders against 
malaria biomarkers were investigated by constructing an 
immune shark  VNAR domains library, selecting high affin-
ity binders against malaria antigens by biopanning, fol-
lowed by protein expression in various Escherichia coli 
expression systems. The binding ability of recombinant 
proteins to target antigens was then compared with a 
commercial mouse mAb.
Methods
Antigens and adjuvants
Recombinant malaria proteins rPfLDH (6  mg/mL), and 
rPvAldolase (1.6 mg/mL) were purchased from Standard 
Diagnostic Inc, Korea. Recombinant protein rPfHRP2 
(5 mg/mL) was produced by Lee [33]. All three proteins 
were diluted in PBS to a final concentration of 250  µg/
mL. Each diluted protein was then aliquoted (1 mL) in a 
fresh 1.5 mL tube and kept at − 20 °C until use. Complete 
Freund’s adjuvant (CFA) and incomplete Freund’s adju-
vant (IFA) were used for shark immunization. CFA was 
only used during the first immunization and replaced by 
IFA during subsequent immune boosting of a wobbegong 
shark. Both CFA and IFA were purchased from Sigma-
Aldrich (USA) and were kept at 4 °C until use.
Immunization of a wobbegong shark
All animal handling work was approved by Animal Ethics 
Committees of UQ and QIMR Berghofer MRI. A banded 
wobbegong shark (Orectolobus ornatus) weighing 2.1 kg, 
was housed at the Moreton Bay Research Station, Uni-
versity of Queensland. The three malaria recombinant 
soluble proteins (rPfHRP2, rPfLDH and rPvAldolase at 
250  µg/mL each) were emulsified in equal amounts of 
CFA and subcutaneously injected in the pectoral fin as a 
mixed-antigens cocktail. Subsequent boosts were admin-
istered intravenously in the caudal vein. To enable pro-
duction of the immune library, the wobbegong shark was 
given an initial injection with 2 mL mixed-antigen cock-
tail into its lateral fin. For subsequent boosts, 1 mL PBS 
containing 250  µg/mL of antigens cocktail was mixed 
with 200  µL IFA and was then injected into the caudal 
vein intravenously at 4-week intervals. To measure the 
humoral response of shark IgNAR against malaria anti-
gens, 3 mL blood sample was drawn from the caudal vein. 
Serum was isolated to determine the reactivity of shark 
IgNAR plasma against malaria biomarkers by ELISA 
using a panel of IgNAR-specific monoclonal antibodies 
(kindly provided by Prof. Flajnik, University of Mary-
land, Baltimore). When sera titres rose to an appropriate 
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level, the shark spleen and peripheral blood lymphocytes 
(PBL) were isolated for construction of the immune  VNAR 
library.
Total RNA extraction and first strand cDNA synthesis
Total RNA extracted from shark spleen and peripheral 
blood lymphocytes (PBL) was pooled and approximately 
20 ng/µL of purified mRNA extracted by Poly(A) Purist 
Kit  (Ambion® Invitrogen, USA) was used as template for 
first strand cDNA synthesis with addition of Leader-F 
primer and C-domain R primer (Table 1). The pre-dena-
turation was set at 94  °C for 2 min. The PCR amplifica-
tion conditions were set at 35 cycles of 30 s at 94 °C, 30 s 
at 55 °C, 1 min at 72 °C, and a final extension was at 72 °C 
for 10 min. The resultant amplicons were separated on an 
agarose gel and the target band was excised and purified 
for library construction.
Construction of shark  VNAR cDNA library
The purified PCR product was then used as a tem-
plate for second PCR using nested primers set (FR1F1 
and FR4R) shown in Table  1. The nested PCR products 
 (VNAR cDNA) were ligated to EcoRI and HindIII linkers 
according to manufacturer’s protocol described in Ori-
entExpress™ cDNA Cloning kit (Novagen, EMD Mil-
lipore Chemicals, USA). After treating with restriction 
enzymes EcoRI/HindIII, the digested product (100  µL) 
were purified by size fractionation through a mini col-
umn filled with gel filtration resin. The purified  VNAR 
cDNA was subsequently ligated into EcoRI/HindIII 
digested  T7Select®1-1b vector. For the ligation reaction, 
a 10 µL reaction mixture was set up according to manu-
facturer’s protocols. On the next day, in vitro Packaging 
of T7 Bacteriophage was performed by adding 5 µL of 
ligated  VNAR/T7Select®1-1b product into 25 µL of Pack-
aging Extract. After incubating at room temperature for 
2 h, the packaging reaction was terminated by adding 270 
µL sterile LB medium and 20 µL chloroform. The mixture 
was mixed well by inversion prior to undertaking the 
plaque assay.
T7 phage biopanning
Three immunotubes (Nunc) coated with 1 mL of recom-
binant rPfHRP2, rPfLDH and rPvAldolase with respec-
tive concentration of 100  µg/mL (Round 1), 50  µg/mL 
(Round 2), 25 µg/mL (Round 3) and 12.5 µg/mL (Round 
4) were incubated overnight at 4  °C on a rotator. After 
washing and blocking, 1  mL of amplified T7 phage dis-
play library (1.5 × 1011 pfu/mL) was added to each immu-
notube and incubated for 1 h at room temperature in a 
rotator. The unbound phage was removed by washing 5 
times with 0.1% PBST (PBS containing 0.1% Tween-20) 
in round one. The number of washes was increased to 10 
times for subsequent rounds of panning. Bound phage 
were eluted with 1  mL of T7 elution buffer (1% SDS in 
TBS) of which 250 µL of eluted phage was used to infect 
host cell BLT5615 (OD 1.0 induced with 1  mM IPTG) 
for amplification. To enrich specific clones, the amplified 
phage was subjected to another three rounds of panning 
as described above. To monitor enrichment, the recovery 
rate of each round of panning was determined by plaque 
assay. The targeted T7 phage was scraped and dispersed 
in 300 µL of phage extraction buffer at 4 °C.
Determination of  VNAR inserts with expected size 
and in‑frame sequence
To determine the DNA sequence of  VNAR insert in T7 
phage, 2 µL of plaque lysate was used as template for 
PCR amplification with addition of T7SelectUP (For) 
and T7SelectDOWN (Rev) sequencing primers. When 
the amplification was completed, 10 µL of PCR reac-
tions were mixed with 1 µL of 10× loading dye and sepa-
rated by 1% agarose gel containing 0.5 µL/mL ethidium 
bromide.  VNAR lengths were then determined visually 
from the agarose gel. PCR product were sequenced as 
described above. The deduced amino acids of  VNAR were 
Table 1 Primers used for shark  VNAR library construction and sequencing
Association  (ka), dissociation rates  (kd), and equilibrium constants  (KD) of mAbs D2, F9, and C1–13 against rPfHRP2. The analysis for mAbs D2 and F9 were undertaken 
using the Octet Red platform, whereas mAb C1–13 was determined by BIAcore
Primers description Nucleotide sequence (5′→3′) Applications
Leader-F ATG AAT ATT TTC TTG CYG TCA GTC C 1st PCR
C-DomainR CCT CTC TGT TCT TCR GTT GCA GAG T 1st PCR
FR1F1 RCA WGG GTR GAC CAA ACA CC Nested PCR
FR4R TTT CAC GGT YAR TRC GGT GCC Nested PCR
T7SelectUP (For) GGA GCT GTC GTA TTC CAG TC T7 Phage sequencing
T7SelectDOWN (Rev) AAC CCC TCA AGA CCC GTT TA T7 Phage sequencing
T7Seq_For TAA TAC GAC TCA CTA TAG GG pET vector sequencing forward
T7Seq_Rev CTA GTT ATT GCT CAG CGG TG pET vector sequencing reverse
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aligned using ClustalW (http://www.ebi.ac.uk/Tools /
msa/clust alw2/) and the plaque containing intact  VNAR 
region was determined using BLAST.
Expression of His6‑tagged H8VNAR protein
Recombinant  VNAR proteins were expressed in bacterial 
cytoplasmic and periplasmic compartment. Briefly, the 
selected  VNAR gene fragment H8VNAR was cloned into 
the expression vectors pET-28a (cytoplasmic expression) 
and pDSB-28Y (periplasmic expression) prior to trans-
formation in E. coli BL21(DE3) competent cells. After 
sequence confirmation of the constructs, the expression 
of His-tagged H8VNAR protein was initiated by inocu-
lating 100 µL glycerol stock of transformed BL21 cells in 
1 L of fresh 2YT medium containing 30 µg/mL kanamy-
cin and incubating at 37  °C with 200 rpm shaking over-
night. The cultures were then induced by IPTG at a final 
concentration of 0.1 mM, followed by an additional incu-
bation at 20 °C, with shaking at 200 rpm for 16 h.
Extraction of protein fractions
Overnight cultures were centrifuged at 6000×g at 4  °C 
in an Ultra Centrifuge (Beckman, USA) for 40  min. To 
extract the soluble protein expressed in cytoplasmic 
compartment, pelleted bacteria were resuspended in 
30  mL cold Tris–phosphate buffer and lysed by passing 
through a French press. To extract periplasmic proteins, 
pelleted bacteria were subjected to an osmotic shock. 
Briefly, pelleted bacteria were resuspended in 30  mL of 
ice-cold TES buffer (0.2  M Tris–HCl pH 8.0, 0.5  mM 
EDTA, 20% sucrose). The cell suspension was incubated 
on ice for 30  min. Cells were lysed by adding 30  mL of 
5 mM  MgSO4 to the cell suspension and further incuba-
tion for 30 min on ice. The slurry was then centrifuged at 
20,000 rpm for 40 min at 4 °C. The resulting supernatant 
was collected and twice filtered through 0.45  µm filter. 
All supernatants collected were then dialyzed overnight 
against protein binding buffer (50  mM Tris–HCl pH 
8.0, 3 mM  MgCl2, 300 mM NaCl) at 4  °C. The purifica-
tion of recombinant His6-tagged H8VNAR protein was 
done using a Nickel-NTA Agarose Resin (Sigma-Aldrich, 
USA), according to the manufacturer instructions.
rPfHRP2‑specific  VNAR protein sandwich ELISA
The purified H8VNAR proteins were analysed by SDS-
PAGE (15%) and Coomassie staining. The concentra-
tion of protein was quantified by Bradford method [34] 
using the Bio-Rad Protein Assay (Bio-Rad Laboratories) 
according to manufacturer instructions. To determine 
the binding efficacy of recombinant antibodies, H8VNAR 
proteins (1 µg/mL or ~ 70 nM) purified from both cyto-
plasmic and periplasmic spaces were used as capture 
antibodies for the anti-rPfHRP2 assays in a sandwich 
ELISA. Tenfold serial diluted recombinant PfHRP2 pro-
teins, with starting concentration at 10  µg/mL, were 
added to each H8VNAR. The commercial mouse mAb 
C1–13 (10  µg/mL or ~ 70  nM) (kindly provided by Dr. 
Martin Bubb, National Bioproducts Institute, South 
Africa) was used to detect captured antigens. The sand-
wich was detected by goat anti-mouse antibody conju-
gated to horseradish peroxidase (HRP) (Jackson, USA). 
Absorbance was read at 405 nm.
Dot blot analysis
A sandwich format of Dot Blot assay was used to deter-
mine the sensitivity of H8VNAR proteins against recom-
binant PfHRP2 protein. Briefly, H8VNAR proteins 
diluted in PBS (~ 70  nM) were transferred onto a pre-
wetted nitrocellulose membrane (Hybond-C, Amersham 
Bioscience, UK) using Dot blotter (BioRad, USA). A two-
fold serial dilution of recombinant PfHRP2 protein was 
added to the H8VNAR proteins. The nitrocellulose mem-
brane was then removed from the blotter and incubated 
with antibody C1–13 (~ 70 nM) at room temperature for 
1  h. Detection of HRP-conjugated secondary antibody 
was performed using ECL chemiluminescence detection 
kit (Amersham Bioscience, USA), following the manufac-
turer’s instructions. The exposed film was developed by 
Kodak X-omat imager.
Results
Immunization of wobbegong shark and IgNAR ELISA 
screening
A wobbegong shark was immunized with three malaria 
antigens, rPfHRP2, rPfLDH, and rPvAldolase. After six 
immunizations over a 7  months period, the antibody 
titre specific to the three malaria biomarker had risen 
compared to the pre-bleed titer, and compared to titters 
in a naïve (non-immunized) wobbegong as a negative 
control. As shown in Fig.  1, IgNAR response against all 
three antigens increased markedly in bleed 4 and 5 com-
pared to pre-bleed and bleed 1. However, antibody lev-
els in bleed 5 were not different to those in bleed 4. The 
highest shark immune response in bleed 5 was observed 
against rPfLDH, followed by rPfHRP2, with the antibody 
titre over 1:51,200 and 1:25,600, respectively. The anti-
rPvAldolase IgNAR titre was lower at 1:12,800. As the 
antibody response was no longer increasing after the fifth 
boost, the spleen and peripheral blood lymphocytes were 
harvested from the immunized shark and the total RNA 
was isolated.
VNAR domains library construction
An immune IgNAR V region  (VNAR) phage display 
library was constructed and screened for  VNARs specific 
to malaria biomarkers. Total RNA was purified from 
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splenocytes and peripheral blood lymphocytes of immu-
nized shark. The successful amplification of  VNAR region 
(nested PCR product) was clearly indicated with a strong 
band present at 340  bp. After digestion with appropri-
ate restriction enzymes, the DNA was cloned into the 
 T7Select®1-1b vector that facilitates expression of phage 
10B-VNAR fusion proteins on the phage surface.
Library characterization
The size of primary library was determined to pos-
sess 1.16 × 106 pfu/mL. PCR screening of 132 randomly 
selected plaques from the primary library revealed that 
approximately 55% (72/132) of the clones contained 
inserts of the expected size at (~ 450  bp) (Additional 
file  1). Nucleotide sequence analysis showed that 82.5% 
(33/40) of isolated fragments contained an in-frame 
sequence, while 17.5% (7/40) contained frameshift muta-
tions. Thus, it was estimated that over 80% of the  VNAR 
library with a size of ~ 5.26 × 105 pfu/mL in 50 mL culture 
encoded functional inserts.
From the  VNAR domains library, the amino acid 
sequences of 33 randomized clones were aligned and 
directly evaluated by comparison with three  VNAR 
domain control genes derived from Orectolobus macu-
lates (wobbegong shark) clones published in the pro-
tein database (PDB), namely AY261681 [32], AY261682 
[32], and AF466395 [17]. The complete two signature 
CDR1 and CDR3 regions and four conserved frame-
work regions (FR) were present in each of the sequenced 
domain of  VNAR. In addition, the hypervariable (HV) 2 
region with shorter length of the amino acid stretch also 
present. Furthermore, most of the clones demonstrated 
unique amino acid sequences, with no identical clones 
detected in the primary library.
Examination of the quality of  VNAR domains library
Significant diversity in the  VNAR domains was observed 
especially in their CDR3 regions. As expected for an 
adult shark, types 1 and 2 but not type 3 of IgNAR rep-
ertoires were represented in the library (Table  2). Con-
sidering the number of non-canonical cysteine (Cys) 
residue(s) encoded within CDR1 and CDR3 regions in 
each  VNAR, approximately 88% of the sequenced clones in 
this library were classified as type 2, whereas 12% were 
classified as type 1. Generally, type 1 IgNAR V regions 
have two non-canonical Cys residues in the CDR3, and 
two additional in FR2 and FR4. Type 2, V regions have 
two non-canonical Cys residues, one each in CDR1 and 
CDR3. Unexpectedly, about 27% (9/33) of the clones in 
this library were found to possess three Cys residues in 
their CDR3 region.
In terms of the length of CDR3 regions, the encoded 
amino acid residues ranged from 10 to 24 in residue 
length, with an average of 17.2 amino acids. Most of the 
CDR3 regions appeared to generate long loops which 
predominantly consisted of 14, 16, 18 and 20 amino acid 
residues. The alignment also showed that a conserved 
canonical Cys residue at the position 22 was consistently 
observed in the C-terminal of CDR1 sequence, while 
mutations were found in the FR regions. Another canoni-
cal Cys residue was also detected at the C-terminal of 
CDR3 regions at position of 84 in all clones studied. The 
 VNAR domains library was evaluated to be of good quality 
because of: (i) the highly variable CDR3 regions, (ii) the 
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Fig. 1 End-titre of shark plasma against three malaria recombinant 
proteins over course of immunization. Shark plasma reacted against 
PfLDH (a), PfHRP2 (b), and PvAldolase (c). The baseline antibody 
response (negative control) was represented by pre-bleed (naïve sera) 
of wobbegong shark. The immobilized 1% BSA was used as negative 
antigen and reacted with serial diluted pre-bleed sera
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presence of type I and type II of IgNAR family, and (iii) 
the position of the conserved canonical C residues being 
similar to the  VNAR sequences published in the protein 
database.
Biopanning of the immunized  VNAR library against three 
malaria biomarkers
To screen for target clones, four rounds of panning were 
performed using an amplified library with the size of 
1.5 × 1011 pfu/mL. Using this approach, target-specific 
clones were obtained for each malaria biomarker. The 
highest phage titre pattern was observed for rPfLDH, 
followed by rPfHRP2 and rPvAldolase as represented 
in Fig. 2. Following four rounds of panning, a total of 30 
single phage plaques, targeting each antigen were sepa-
rately picked for further analysis by PCR screening and 
sequencing. The results indicated that 20 anti-rPfHRP2 
clones, 18 anti-rPfLDH clones, and 15 anti-rPvAldolase 
Table 2 Deduced amino acid sequences in hypervariable regions of  VNAR clones randomly selected from primary library
Clone CDR1 HV2 CDR3
CDR3 length 
and number 
of cysteine
Type
Lib_A1 DASYGLCS TNEQTISIG ETFGGDDGSGIFCPGNY 17–1 2
Lib_A2 DATCGLYS TNEQTISIG GADDDSCNSHGVIGYH 16–1 2
Lib_A3 DSPHGLCS TNEQRISIG EACDDPIATRLPERYE 16–1 2
Lib_A4 DTNYELCN TNDQRISIG EGCERKLASVPHRWSDYVI 19–1 2
Lib_A5 DTKYPLC TNEQRISIG GADDYDSCYYSGVMCYYY 18–2 2
Lib_A6 DTRYGLCD TMEQRISIG EACDDSDCAAIGMDVFCE 18–3 2
Lib_A7 DTDWGLCN TIEQRISIG ETCETYADYCCWGDYQ 16–3 2
Lib_A8 DGDCGLYR TVEQTIPIV GARSCYTVYY 10–1 2
Lib_A9 GTSYALCG TNEQTISIG EACDDLCYGDYCGEWSGYVE 20–3 2
Lib_A10 DASCGLYS TNELDISIV ETSPICDGWSPHGE 14–1 2
Lib_B1 DTSHVLCT TNEQRVSIG EACEGYSDSDCGCIYPYE 18–3 2
Lib_B2 DTIYKFCN TNEETISIG KAYDYEKDCIGGVISPYYYE 20–1 2
Lib_B3 DTRYGLYN TNEQRISIG GACDAYHDGSGVPRSCAY 18–2 1
Lib_B4 ESFYGLCA TNEQRLSIG EACDEDSDFVKLEWYD 16–1 2
Lib_B7 QTAYKLCS TNELGISIA QAYDSDCAVLWSGDKY 16–1 2
Lib_B9 DTRYGLCS TNEQRISIG EAFCGSSYYYE 11–1 2
Lib_B10 DTEFGVCS RNEQRLSIG EASPYCDGWSPNGD 14–1 2
Lib_C1 DTSYGLCT TNEQRISIG ETCPHSHSDCGICPLAGFYYE 21–3 2
Lib_C2 NAKCGLYT TNEQTISIG GVDDDGEGTSCYGPGWL 17–1 2
Lib_C3 RSSEGLCT TNEQRISIG GADDRGYDGNCYWDQY 16–1 2
Lib_C4 DGDCGLYR TNEDRIEIE GGVDRGITTMWGTCIGAELG 20–1 2
Lib_C7 DTTYYLYS TNEQRISPG GAWSISTAGPAVNY 14–0 1
Lib_C8 DPTCGLYD SNEQTISIG GGRDGRYDGYNCSPRPGYFY 20–1 2
Lib_C9 NSECGLLS TNEQEISIG VADDNNYNSDAEYSCDGQEVISH 23–1 2
Lib_C10 DAKYGLVR TNEQRISIG ETSPYCDGWSPNGD 14–1 1
Lib_D1 DTRYELCN TNEQRISIG EACDERYSDCGFCDSIAV 18–3 2
Lib_D3 DASCGLYR TNEQRISIG EACSLSDCRAYCVRGDYE 18–3 2
Lib_D4 DTSYGLCT TNEQRISIG ETCTLYSDCRDCDAWR 16–3 2
Lib_D5 DTVYGLCK TNEQTISIG ELRATLTAYCDIGKSGHYE 19–1 2
Lib_D6 DTKYGLCT TNEQTISIG GVEDAYSYDGKGPEAPCSWSVDYH 24–1 2
Lib_D7 DTPYGLCS TNEQIISIG GAGTYVATSCAAGVGY 16–1 2
Lib_D9 DKNYGLFR TNEERIEIG ETCETYADYCCWGDYQ 16–3 1
Lib_D10 DTIYAFCN TNEQTISIG EACEYSTVDLWSDTYYYE 18–1 2
The non-canonical cysteine residue is highlighted in red color. This table also indicates the length of CDR3, number of cysteine residue, and type of IgNAR family for 
each clone
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clones had the expected size and in-frame (ORF) 
sequences. Only the in-frame clones were chosen for fur-
ther analysis.
Competitive biopanning
To avoid cross-reactivity of non-specific clones, a com-
petitive biopanning was applied to further select the 
strongest unique binders. Briefly, three more rounds of 
biopanning were carried out by immobilizing the tar-
get proteins in immunotubes as described in section T7 
Phage Biopanning. Of 53 selected clones isolated from 
the previous panning, 26 clones with distinct sequence 
were pooled and subsequently tested for competitive 
binding to either their putative target ligand or to the 
other two ligands, to which no binding should occur.
Competitive biopanning resulted in 26 clones retained 
after four rounds of panning. When inspecting the ratio 
of specific to non-specific binding of the resultant clones, 
four of the 26 clones were identified to be predominantly 
reacting to one specific antigen: H8 as an anti-PfHRP2 
clone, P16 and P2–3 as anti-PfLDH clones, and A4–3 as 
an anti-PvAldolase clone (Fig. 3). The clones that showed 
binding to all antigens such as clones A5–3 and A7–3 
were eliminated from further analysis.
Sequence analysis of targeted clones
The amino acid sequence of the four final clones isolated 
following competitive biopanning were aligned (Fig.  4). 
The clones were found to lack Cys residues in FR2 and 
FR4 regions. However, inspection of CDR regions 
revealed that all clones had conventional type 2 IgNAR 
V regions. No major mutations were identified in FR1, 
FR2, FR3 and FR4 regions of clones P16, P2–3, and A4–3, 
except for the FR3 region of H8 clone.
Enrichment of T7 Phage by Biopanning
against Malaria Antigens
1 2 3 4
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Fig. 2 Selection and enrichment of malaria biomarker specific 
T7 phage after four rounds of biopanning. A plaque assay was 
performed to measure the size of eluted phage after each round of 
panning, and the size of amplified phage. The enrichment fold was 
calculated by dividing the eluted phage by input library size
Fig. 3 Competitive biopanning between 26 selected T7 specific clones. Twenty-six cloned selected from initial four rounds of biopanning against 
three different malaria biomarkers were pooled. This pool was tested competitively to select the specific clones, based on high frequency of 
appearance and absence of cross-reactivity. The colour bars represent the clones isolated from biopanning against different malaria antigen 
proteins (blue: anti-PfHRP2; red: anti-PfLDH; green: anti-PvAldolase). Yellow arrows point to four clones identified to be specific (H8 as an anti-PfHRP2 
clone, P16 and P2–3 as anti-PfLDH clones, and A4–3 as an anti-PvAldolase clone)
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In terms of number of Cys residue, H8 contained four 
residues in CDR3 region, the largest numbers of Cys 
residues observed in this library. In comparison, three 
Cys residues were detected in clone P2–3, and only 
one in clones P16 and A4–3. All clones were observed 
to have longer amino acid residues stretches in CDR3 
which were more than the average of 17 amino acids of 
the  VNAR library (Fig. 5). The longest CDR3 were H8 and 
A4–3 with 20 residues, followed by P16 with 19 residues, 
and P2–3 with 17 residues. Being a highly dominant 
clone with an average appearance higher than 85% after 
each round of panning, H8 was selected for recombinant 
protein production.
Protein expression and purification
The expression and purification of H8VNAR using two 
different expression vectors yielded a clearly visible band 
on SDS-PAGE stained with Coomassie Blue (Figs. 6, 7). 
All H8VNAR proteins were present as well defined single 
bands at around 14 kDa in size, corresponding to the pre-
dicted molecular mass of H8VNAR including the 6× His 
tag (13.57 kDa). In Western Blot analysis, a “split” band 
was detected in the IPTG-Induced total cell lysates of E. 
coli processed for periplasmic expression (Fig.  7). How-
ever, this phenomenon was not observed in the cyto-
plasmic expression system (Fig.  6). Nevertheless, only a 
single band was detected in both H8VNAR proteins after 
purification, suggesting the soluble of recombinant  VNAR 
proteins can be obtained using bacterial expression sys-
tem. No leakage of proteins from expression hosts could 
be observed. However, prolonged expression can lead to 
protein aggregation that eventually resulted in the forma-
tion of inclusion body in the E. coli expression host.
Binding efficiency by sandwich ELISA
The binding ability of recombinant  VNAR proteins was 
determined on ELISA plates in a sandwich format. The 
binding efficiency was compared with commercial mAb 
C1–13 that performed in an indirect ELISA format. From 
the screening assay, both  VNAR proteins gave positive 
responses when read on plate readers at OD 450 nm. The 
recombinant H8VNAR protein purified from periplasmic 
space showed better performance than that of cytosolic 
recombinant H8VNAR in terms of absorbance (Fig. 8a). 
At a concentration of rPfHRP2 of 1 µg/mL, the OD read-
ing of periplasmic  VNAR protein (~ 0.58) was about two-
fold higher than that of protein produced by cytoplasmic 
expression (~ 0.32). However, these reactivities of the 
 VNAR proteins are inferior to the reactivity of mAb C1–13, 
the positive control in this experiment (OD of ~ 1.4 at the 
same concentration of rPfHRP2) (Fig. 8b). All OD read-
ings demonstrated decreasing signal proportionally with 
Fig. 4 Deduced amino acid residues of four clones isolated after competitive biopanning. The PfHRP2-specific clone was represented by H8; The 
PfLDH-specific clones were P16 and P2–3; the PvAldolase-specific clone was A4–P4. All FR regions are shown by orange bar. The CDR regions are 
shown by red box. The canonical cysteine residues in FR1 and FR3 regions are highlighted in green. The non-canonical cysteine residues in CDR1 
and CDR3 regions are highlighted in yellow background. The mutation sites in FR3 region of clone H8 is highlighted in pink background
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reducing concentrations of rHRP2. No specific binding to 
BSA was observed for both recombinant H8VNAR pro-
teins or mAb C1–13.
Detection sensitivity by dot blot assay
To further determine the detection sensitivity of recom-
binant antibodies, both cytosolic and periplasmic 
H8VNAR proteins were deployed as capture antibodies 
and examined in Dot Blot assay (Fig. 9). All recombinant 
antibodies reacted with rPfHRP2 protein showing differ-
ent intensities similar to that observed in ELISA. Mouse 
mAb C1–13 showed the highest response with detec-
tion below 5 ng/mL. In contrast, the H8VNAR proteins 
exhibited lower binding affinity, even different binding 
reactivity was observed in both cytosolic and perisp-
lamic produced H8VNAR proteins. The H8VNAR pro-
teins produced in periplasmic space showed binding to 
the rPfHRP2 at a lowest concentration of 78  ng/mL. In 
comparison, the detection limit for the H8VNAR pro-
tein expressed in cytoplasm was 312 ng/mL. As expected, 
none of the recombinant antibodies tested reacted with 
1% BSA, the negative control. Based on this observa-
tion, it was concluded that the sensitivity of periplasmic 
produced H8VNAR protein was superior to that of cyto-
solic protein, however both were less reactive than mAb 
C1–13. More Western Blot assays, designed to investi-
gate possible cross reactivity to other malaria biomarker 
proteins for all of the selected  VNAR clones are planned. 
Further biological functions to investigate include reac-
tivity for the native malaria protein, and thermostabil-
ity will provide more insight in the diagnostic value of 
recombinant H8VNAR to rPfHRP2.
Discussion
The small antigen binding domains of shark IgNAR 
 (VNAR) have some unique properties in terms of thermo-
stability and refolding capacity, which make them ideal 
antibody-based diagnostic tools. Hence, they have gained 
the interest of researchers focused on developing new 
binders for targeting antigens from various diseases. This 
study describes shark  VNAR antibodies that are specific 
against malaria antigens were successfully isolated and 
produced recombinantly in E. coli.
Following immunization of a wobbegong shark (Orec-
tolobus ornatus) with three malaria biomarker proteins, 
the levels of IgNAR response against malaria recombi-
nant PfLDH and PfHRP2 significantly increased in the 
wobbegong shark after the third immunization (Fig.  1), 
suggesting that the wobbegong shark could mount a 
humoral protective response to these antigens [35]. The 
fact that it took at least 3 boosts to observe an antibody 
response is likely due to sharks having a unique immune 
system where the antibody serum levels generally climb 
slowly compared to mammals. Therefore, it can take 
months until a significant antigen-specific titre is reached 
[36]. This phenomenon had also been indicated in work 
using hen egg lysozyme (HEL) to immunize nurse shark 
[25, 37–39]. This is presumably because pentameric IgM 
is responsible for providing early protection with high 
avidity interaction against invading pathogen in carti-
laginous fish. In contrast, monomeric IgM likely IgG in 
mammals, and IgNAR are responsible for specific and 
high affinity binding response [35]. From these results, 
it is apparent that the immune system of the wobbegong 
shark studied herein was comparable to other shark fami-
lies and appropriate IgNAR responses were identified.
After purification of mRNA from shark spleen, a 
 VNAR phage display library was successfully constructed 
using a T7 phage display system. Using this system, 
 VNAR displayed on the surface of T7 bacteriophage do 
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Fig. 5 Analysis of deduced amino acids of  VNAR clones selected after 
four rounds of biopanning. a The number of cysteine residues and b 
represents the length of the CDR3 region encoded within the  VNAR 
clones
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not need to be extracted from the periplasmic layer of 
host cells which is a necessary step in M13 filamentous 
phage [40, 41]. Therefore,  VNAR fusion phage particles 
could directly be obtained through cell lysis. The func-
tional phage titer yielded in this  VNAR domains primary 
library was estimated to have 5.3 × 105 independent 
clones which is slightly lower than that of the librar-
ies derived from naïve [28] and immunized [25] shark 
using M13 phage display system, and synthetic sharks 
using T7 phage display system [39]. Therefore, it was 
assumed that the library size may partly be influenced 
by factors such as packaging efficiency and phage dis-
play system (M13 or T7). In contrast to VH and VL 
genes in conventional antibody libraries, the genes 
encoding  VNAR repertoires were easier to clone [25, 
41] with only two pairs of primers required to access 
the diversified shark immunoglobulin genes by PCR 
amplification of the  VNAR fragments from the spleen 
and PBL of immunized shark.
Sequence analysis indicates that about 90% of the 
clones in this library belonged to type 2 NAR. These data 
are in agreement with other  VNAR libraries derived from 
wobbegong sharks, indicating that the genes encoding 
IgNAR in the wobbegong family are prone to produce 
type 2 NAR domain [31]. However, genes encoding type 
1 NAR representatives are commonly confined to nurse 
sharks [25]. In addition, about 27% of the clones in this 
library were found to possess three Cys residues in their 
CDR3 region. Although this number has rarely been 
described in IgNAR, Diaz et al. have previously reported 
it was found in some hypermutated clones in a nurse 
shark IgNAR [42].
In comparison with the human VH gene family, a higher 
degree of divergence in framework and hypervariable 
- +              
Fig. 6 Expression and purification of recombinant cytosolic H8VNAR using pET-28a vector. Proteins were separated on 15% SDS-PAGE and stained 
with Coomassie Blue (left panel). H8VNAR was detected by Western Blot with anti-His tag antibody and a ~ 14 kDa band clearly apparent. Lane 1 
represents total protein from non IPTG-induced bacteria cells; lane 2 represents total protein from IPTG-induced bacteria cells; and lane 3 represents 
purified cytosolic H8VNAR protein
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regions is exhibited in shark  VNAR. First, the hypervariable 
regions of  VNAR are on average longer than those in VH. The 
average CDR3 length in conventional human and mouse 
VH is 12 and nine amino acids, respectively [43], whereas 
the length of shark  VNAR observed in this study was about 
16–18 amino acids and in an agreement with those reported 
previously [25, 31, 42]. The hypervariability detected within 
CDR3 in  VNAR against malaria antigens after repetitive 
rounds of panning, suggests that these residues are contact-
ing the antigen and that the somatic hypermutations in this 
region will take place during the affinity maturation [14, 32]. 
Furthermore, the enrichment of disulfide bridge in the long 
CDR3 region may cause the formation of disulfide loops 
that resulted to type 1 or type 2  VNAR proteins configuration 
[44]. Therefore, to examine the quality of the  VNAR domain 
library constructed, the diversity in the CDR3 region, 
the different isotypes, and the position of the conserved 
canonical Cys residues were analysed and compared with 
other  VNAR domains that published in protein database.
Four rounds of biopanning resulted in the enrichment 
of antigen-specific phage antibodies directed against 
rPfHRP2, rPfLDH, and rPvAldolase proteins (Fig.  2). 
Interestingly, the pattern of enrichment was similar to the 
end titer of polyclonal IgNAR responses in  vivo where 
the highest titers was rPfLDH-specific, rPfHRP2-spe-
cific, and followed by rPvAldolase-specific  VNAR clones. 
From this point of view, it is postulated the immunization 
process is an important factor to generate the high affin-
ity single domain clones [25, 45]. In contrast to “naïve” 
antibody libraries, lesser rounds of panning cycles were 
needed to produce a highly specific signal which is in 
agreement with that reported from other immune phage 
display libraries [46]. Thus, the rapid selection of spe-
cific  VNAR-displayed phage suggests that antigen-specific 
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Fig. 7 Expression and purification of recombinant periplasmic DsbA-H8VNAR using pDSB-28Y vector. Proteins were separated on 15% SDS-PAGE 
and stained with Coomassie blue (left panel). DsbA-H8VNAR was detected by Western Blot with anti-His tag antibody and a ~ 14 kDa band clearly 
apparent. Lane 1 represents total protein from non IPTG-induced bacteria cells; lane 2 represents total protein from IPTG-induced bacteria cells; and 
lane 3 represents purified periplasmic DsbA-H8VNAR protein
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clones are well represented within the  VNAR population. 
The use of the T7 phage system has an advantage over 
M13 filamentous phage. In this system, phage amplifica-
tion takes shorter time, and cell lysis can be observed by 
a visible reduction in OD of the culture after incubation.
The sequencing alignment revealed that all 26 clones 
specific to a malaria antigen protein were in-frame. Two 
distinct clones were identified targeting the recombi-
nant rPfHRP2, whereas twelve clones each to targeting 
rPfLDH and rPvAldolase proteins. The amino acid resi-
dues found in the CDR3 regions differed for each antigen 
confirming that the CDR3 region is a major determining 
factor for the antigen binding specificity [47]. Moreo-
ver, the extraordinary length of CDR3 in shark  VNAR has 
been exhibited potentially penetrating into the cavities of 
antigen [48]. All of the selected  VNAR clones, except P9 
and A9–3, appeared to contain at least one Cys residue 
in the CDR1 and CDR3 regions, suggesting that these 
clones belong to type 2 NAR family and are proposed 
to form an interloop of disulfide bond [49]. The length 
of the selected clones 10 to 24 amino acid residues with 
a mean of 17 amino acids (Additional file  2), indicating 
that longer hypervariable regions of the  VNAR could aid 
enlarging the actual surface of the antigen binding site, 
and that this might compensate for the absence of the 
antigen-binding surface area provided by the VL domain 
in conventional Fv of IgG [14, 31, 42].
Despite most of the selected clones demonstrating a 
positive response to corresponding antigen in monoclo-
nal ELISA screening, it was difficult to differentiate the 
genuine clones from “sticky” clones using the phage dis-
play system. This phenomenon is observed quite often 
with phage display [50, 51]. Indeed, selection of highly 
cross reactive clones could possibly lead to production of 
recombinant  VNARs with inferior binding affinity. Another 
limitation observed with this T7 phage display system was 
the difficulty in isolating high affinity binders that con-
tained disulfide bonds. The T7 phage display system is 
therefore more suitable for use in peptide discovery rather 
than antibody surface display [52, 53]. The polypeptides 
produced by T7 phage display system are synthesized in 
the reducing cytoplasmic environment of the host E. coli, 
which differs from phage secretion via the periplasmic 
space, as occurs in the filamentous M13 phage system. As 
a consequence, the proteins displayed on the surface of T7 
phage may not be properly folded and therefore not ide-
ally suited for functional screening for high affinity  VNAR 
clones. Because misfolded  VNAR presented on the surface 
of the T7 capsid could lead to false-positive plaques, addi-
tional rounds of competitive biopanning were undertaken 
to guarantee the specificity of targeted clones. In addition, 
the subsequent production of recombinant  VNAR proteins 
was performed in an alternate expression system.
H8VNAR was one of the highest affinity clones, and also 
the most frequently isolated during panning. In this clone, 
seven Cys residues were observed and predicted to form 
three disulfide bridges in its molecular structure. This pre-
diction was done by DiANNA 1.1 Web Server (http://clavi 
us.bc.edu/~clote lab/DiANN A/), a bioinformatics tool 
which is available online. Formation of disulfide bonds is 
known to be problematic in bacterial expression systems 
for eukaryotic proteins, particularly antibody fragments 
[54]. To achieve optimal folding, the production of pro-
teins containing disulfide bonds needs to be manipulated 
in an oxidative environment of E. coli cells.
To make this possible, a signal sequence DsbA peptide 
was added to express PfHRP2-specific H8VNAR protein 
in E. coli. The recombinant H8VNAR expressed in peri-
plasmic and cytoplasmic was then examined for their 
yield and binding activity. A periplasmic protein with 
an expected band at ~ 14 kDa was visible on SDS-PAGE 
(Fig. 7), suggesting that adding the DsbA signal sequence 
has efficiently directed  VNAR protein from cytoplasmic 
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Fig. 8 Comparison of binding efficiency of recombinant H8VNAR 
proteins with commercial mouse mAb C1–13 against tenfold serial 
diluted HRP2 proteins by ELISA. a The binding reactivity of purified 
cytosolic and periplasmic H8VNAR proteins was performed in a 
sandwich ELISA format. b The binding reactivity of positive control 
mAb C1–13 was performed in an indirect ELISA format. 1% BSA was 
used as negative antigen for rPfHRP2
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into the periplasmic space via the co-translational SRP 
pathway [55]. Thus, crystallography is planned to deter-
mine the conformation of recombinant H8VNAR and 
verify the presence of disulfide bond in this protein 
molecule.
When comparing the cytosolic H8VNAR and the 
periplasmic H8VNAR (or DsbA-H8VNAR), the bind-
ing capacity of DsbA-H8VNAR to recombinant PfHRP2 
protein in Dot Blot assays was shown superior to that of 
cytosolic H8VNAR protein (Fig. 9). This insight indicated 
that periplasmic expression may potentially lead disulfide 
bond formation and proper folding of the protein thereby 
increasing the reactivity of recombinant antibody against 
the antigen epitopes [56, 57].
Conclusion
In this work, the ability to raise the specific IgNAR from 
shark against malaria biomarker proteins by immuni-
zation was demonstrated. Meanwhile, a phage display 
 VNAR library was also successfully constructed by over-
lap extension PCR. Selection from this library resulted 
in several unique clones with specificity for each of three 
malaria antigens, suggesting the enrichment of affin-
ity clones against malaria antigen proteins has been 
achieved by iterative biopanning and subsequent com-
petitive biopanning. Also, the utilization of the DsbA 
signal peptide caused expression of soluble recombinant 
shark  VNAR proteins by enhancing folding capability was 
evidenced in the screening assays. Despite further opti-
mization conditions under investigation, these findings 
and insights imply the expression of shark  VNAR is pos-
sible using the system designated in this study. The bind-
ing specificity and sensitivity of recombinant H8VNAR 
to the rPfHRP2 protein was demonstrated in a sandwich 
ELISA and a Dot Blot assay, respectively. Despite of that, 
further engineering including mutagenesis is planned in 
respect to improve the biological activity of H8VNAR 
towards malaria biomarker protein. Currently, a new 
semi-synthetic shark  VNAR library using M13 phagemids 
is being constructed whereby the performance of new 
clones against malaria antigens will then be presented.
Additional files
Additional file 1. PCR amplification of randomly selected plaques from 
the  VNAR domains primary library using T7SelectUP (For) and T7Select-
DOWN (Rev) sequencing primers. Lane M represents 100 bp ladder; lane 
1–20 represents insert of single plaque; lane −ve represents negative 
control (PCR product with no cDNA template).
Additional file 2. Deduced amino acid sequences in hypervariable 
regions of  VNAR clones targeting to three malaria biomarkers. The non-
canonical cysteine residue is highlighted in red colour. This table also 
indicates the length of CDR3, number of cysteine residue, and type of 
IgNAR family for each clone.
Fig. 9 Comparison of binding reactivity of recombinant purified cytosolic and periplasmic H8VNAR against twofold serial diluted rPfHRP2 proteins 
in Dot Blot analysis. mAb C1–13 was a positive control. 1% BSA was a negative control
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